← Volver a la portada
Asia · Mercados regionales · CNBC-TV18

Laurus Labs shares recover more than 50% of Monday's fall after promoter rules out further stake sale

Publicado por CNBC-TV18 · India hace 2 h
Laurus Labs shares recover more than 50% of Monday's fall after promoter rules out further stake sale - CNBC TV18
Laurus Labs shares recover more than 50% of Monday's fall after promoter rules out further stake sale - CNBC TV18 · CNBC-TV18

Resumen detallado

Laurus Labs has earmarked a capital expenditure of ₹2,000 crore for FY27, which will scale up to over ₹3,000 crore in FY28. The entire expansion outlay will be funded through internal accruals, avoiding incremental balance sheet stress, Chava stated.

Laurus Labs promoters have no plans for any further stake reduction in the company, the management told CNBC-TV18 on Tuesday, seeking to assuage investor concerns following a sharp sell-off in the stock during the previous trading session.

The stock has now moved to the highs of the day, gaining as much as 4%, after falling nearly 9% on Monday, marking its biggest single-day drop since January 2025. The fal came after promoter Satyanarayana Chava and other members linked to the promoter group, sold nearly 20 lakh shares of the company on November 11, as per NSE disclosures.

Clarifying the rationale behind the recent equity dilution, Laurus Labs promoter Satyanarayana Chava stated that the stake sale was executed strictly to pare down personal debt and fund philanthropic initiatives. Reaffirming confidence in the business trajectory, Chava noted that Laurus Labs has evolved into a fully integrated Contract Development and Manufacturing Organization (CDMO) player and expressed satisfaction with its current operational momentum in the segment.

Addressing questions around capital allocation, the management emphasized transparency on its expansion plans and laid out a multi-year investment pipeline:

The company has earmarked a capital expenditure of ₹2,000 crore for FY27, which will scale up to over ₹3,000 crore in FY28. The entire expansion outlay will be funded through internal accruals, avoiding incremental balance sheet stress, Chava stated.

Despite the heavy capex, Gross and EBITDA margins are expected to remain stable at current levels over the next few quarters. Chava added that he does not foresee any dilution in return ratios going forward.

Shares of Laurus Labs are now trading 4.6% higher on Tuesday after the management interaction with CNBC-TV18 at ₹2,321.4. The stock had made a record high of ₹2,488 last Friday.

Kotak Mutual Fund expands SIF offering with this new fund; check details here

Where to invest now: Ashika's Rahul Arora picks banking, FMCG and liquor stocks

Inicio del artículo, extracto de CNBC-TV18. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en CNBC-TV18 Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.cnbctv18.com)

También te puede interesar